Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million.
Meitheal spun out Xentria in 2020, according to Crain’s Chicago Business.
The companies, both of which are based in Chicago, said Tuesday that they entered into an exclusive multi-year licensing agreement to commercialize Xentria’s lead candidate, XTMAB-16, which is being tested as a treatment for a rare lung disease that commonly occurs in women and African American patients. The monoclonal antibody is set to enter a Phase II clinical trial later this year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters